Status: Recruiting
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
This research study will test the safety and anticancer activity of the combination of three drugs (Roginolisib, Venetoclax, and Rituximab) for participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL). The names of the study drugs involved in this study are: * Roginolisib (a novel type of PI3-kinase delta inhibitor) * Venetoclax (a type of B-cell lymphoma 2 inhibitor) * Rituximab (a type of monoclonal antibody)
Participants needed: 64
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Jennifer R. Brown, MD, PhDUpdated: Feb 11, 2026Locations: 1
Eligibility criteria
Patients with relapsed/refractory CLL who meet iwCLL criteria for requiring trea... [+20]
Patients who have received prior treatment with venetoclax or PI3K inhibitors in... [+22]